2. Epigenetics
  3. Epigenetic Reader Domain
  4. BET BD2-IN-1

BET BD2-IN-1 (compound 45) is a potent and selective inhibitor of BET BD2 (IC50=1.6 nM). BET BD2-IN-1 inhibits the differentiation of Th17 cells by decreasing the activation of STAT3 and NF-κB. BET BD2-IN-1 is used in psoriasis and inflammatory bowel disease (IBD) research.

For research use only. We do not sell to patients.

BET BD2-IN-1 Chemical Structure

BET BD2-IN-1 Chemical Structure

CAS No. : 2677039-24-4

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BET BD2-IN-1 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BET BD2-IN-1 (compound 45) is a potent and selective inhibitor of BET BD2 (IC50=1.6 nM). BET BD2-IN-1 inhibits the differentiation of Th17 cells by decreasing the activation of STAT3 and NF-κB. BET BD2-IN-1 is used in psoriasis and inflammatory bowel disease (IBD) research[1].

IC50 & Target

BRD2 BD1

570 nM (IC50)

BRD2 BD2

5.9 nM (IC50)

BRD3 BD1

465 nM (IC50)

BRD3 BD2

6.0 mM (IC50)

BRD4 BD1

524 nM (IC50)

BRD4 BD2

1.6 nM (IC50)

BRDT BD1

527 nM (IC50)

In Vitro

BET BD2-IN-1 (500 nM) effectively inhibits Th17 cell differentiation and has excellent selectivity for BD2 over BD1[1].
BET BD2-IN-1 (4 nM) binds to BRD4 BD2 in intact cells and has stabilization effect on BRD4 BD2[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BET BD2-IN-1 Related Antibodies

Cell Differentiation Assay[1]

Cell Line: Th17 cells
Concentration: 500 nM
Incubation Time:
Result: Showed the strongest inhibitory activity and reduced differentiation from 19.0 to 7.81%.

Cell Migration Assay [1]

Cell Line: HEK 293 T cells
Concentration: 4, 20, 100, 500, 2500, 10000 nM
Incubation Time: 30 min
Result: Stabilized BRD4 BD2 at 50.4 °C.
In Vivo

BET BD2-IN-1 (20 mg/kg for i.v; once daily for seven days) inhibits the protein expression of p-STAT3 and p-NF-κB in mouse skin tissues, effectively ameliorates the pathological changes in the psoriasis mouse model[1].
BET BD2-IN-1 (20 mg/kg for i.v; once daily for seven days) significantly decreases the disease activity index (DAI) score in dextran sulfate sodium (DSS) induced IBD mouse model[1].
Pharmacokinetic Analysis of BET BD2-IN-1 in Sprague Dawley Rats Model[1]

parameter AUC(0‑t) (ng•h/mL) C0 (ng/mL) T1/2 (h) CL (mL/kg/min) Vdss (L/kg)
iv(1 mg/kg) 272 ± 7.2 279 ± 78 1.5 ± 0.1 60 ± 2.0 6.6 ± 0.8
parameter AUC(0‑t) (ng•h/mL) Cmax (ng/mL) T1/2 (h) Tmax (h) F (%)
po(10 mg/kg) 78 ± 34 20 ± 11 1.9 ± 0.2 2.7 ± 1.2 2.9 ± 1.2

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Imiquimod (HY-B0180)-induced Psoriasis mouse model[1]
Dosage: 10 and 20 mg/kg
Administration: Intravenous injection (i.v.) ; Once daily for seven days
Result: Significantly alleviated the Imiquimod-induced skin lesions in a dose-dependent manner.
Obviously reduced the enlarged spleen.
Significantly decreased the expression of p-STAT3 and p-NF-κB in mouse skin tissues.
Animal Model: DSS (HY-116282C)-induced IBD mouse model[1]
Dosage: 10 and 20 mg/kg
Administration: Intravenous injection (i.v.) ; Once daily for seven days
Result: Effectively prevented colon shortening.
Effectively alleviated the DSS-induced weight loss.
Significantly alleviated the infiltration of inflammatory cells, areas of ulceration as well as loss of mucosal epithelium, and goblet cells caused by DSS.
Molecular Weight

478.58

Formula

C30H30N4O2

CAS No.

2677039-24-4

SMILES

O=C(C1=CC=CC(CN2C3=C(C=C4C5=C2C=CC=C5C(N4C)=O)C=CC=C3)=C1)NC6CCN(CC6)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BET BD2-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BET BD2-IN-12677039-24-4Epigenetic Reader DomainBET BD2PsoriasisInflammatory Bowel DiseaseIBDInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BET BD2-IN-1
Cat. No.:
HY-155680
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.